PMID- 38047977
OWN - NLM
STAT- MEDLINE
DCOM- 20240111
LR  - 20240111
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 24
IP  - 12
DP  - 2023 Dec
TI  - Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid 
      Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and 
      Treatment Strategies.
PG  - 1720-1738
LID - 10.1007/s11864-023-01149-1 [doi]
AB  - The introduction of TKIs into the therapeutic armamentarium of CML has changed 
      the disease paradigm, increasing long-term survival from 20% to over 80%, with a 
      life expectancy now approaching that of the general population. Although highly 
      effective, TKIs also have a toxicity profile that is often mild to moderate, but 
      sometimes severe, with multiple kinases involved in the development of adverse 
      events (AEs). Among others, cardiovascular AEs observed in TKI-treated CML 
      patients may represent a significant cause of morbidity and mortality, and their 
      pathogenesis is still only partially understood. In view of the recent 
      introduction into daily clinical practice of new TKIs, namely the STAMP inhibitor 
      asciminib, with a distinct safety profile, hematologists now more than ever have 
      the opportunity to select the most suitable TKI for each patient, an aspect that 
      will be fundamental in terms of personalized preventive and therapeutic 
      strategies. Furthermore, physicians should be aware of the feasibility of TKI 
      dose modifications at all stages of the patients' treatment journey, both at 
      diagnosis for frail or elderly subjects or with multiple comorbidities, and 
      during follow-up for those patients who experience toxicity, as well as to 
      prevent it, with the main objective of reducing side effects while maintaining 
      the response. Consequently, preserving the cardiovascular health of CML patients 
      will likely be a more urgent topic in the near future, with specific measures 
      aimed at controlling cardiovascular risk factors through a multidisciplinary 
      approach involving a panel of healthcare professionals together with the 
      hematologist.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Iurlo, Alessandra
AU  - Iurlo A
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Via Francesco Sforza 35, 20122, Milano, Italy. 
      alessandra.iurlo@policlinico.mi.it.
FAU - Cattaneo, Daniele
AU  - Cattaneo D
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Via Francesco Sforza 35, 20122, Milano, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
FAU - Bucelli, Cristina
AU  - Bucelli C
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Via Francesco Sforza 35, 20122, Milano, Italy.
FAU - Spallarossa, Paolo
AU  - Spallarossa P
AD  - Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino - Italian 
      IRCCS Cardiology Network, Genova, Italy.
FAU - Passamonti, Francesco
AU  - Passamonti F
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Via Francesco Sforza 35, 20122, Milano, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231204
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Tyrosine Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Antineoplastic Agents/adverse effects
MH  - Tyrosine Kinase Inhibitors
MH  - Clinical Relevance
MH  - Protein Kinase Inhibitors/adverse effects
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/drug therapy
OTO - NOTNLM
OT  - Adverse events
OT  - Cardiovascular
OT  - Chronic myeloid leukemia
OT  - Tyrosine kinase inhibitors
EDAT- 2023/12/04 12:43
MHDA- 2024/01/11 07:42
CRDT- 2023/12/04 11:07
PHST- 2023/11/12 00:00 [accepted]
PHST- 2024/01/11 07:42 [medline]
PHST- 2023/12/04 12:43 [pubmed]
PHST- 2023/12/04 11:07 [entrez]
AID - 10.1007/s11864-023-01149-1 [pii]
AID - 10.1007/s11864-023-01149-1 [doi]
PST - ppublish
SO  - Curr Treat Options Oncol. 2023 Dec;24(12):1720-1738. doi: 
      10.1007/s11864-023-01149-1. Epub 2023 Dec 4.